查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1711654

病患來源異質骨移植/PDX 模型市場分析及預測（至 2034 年）：類型、產品、服務、技術、應用、最終使用者、階段、組件、流程

Patient-Derived Xenograft/PDX Model Market Analysis and Forecast to 2034: Type, Product, Services, Technology, Application, End User, Stage, Component, Process
出版日期: | 出版商: Global Insight Services | 英文 338 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

患者異質骨移植/PDX 模型市場預計將從 2024 年的 18 億美元成長到 2034 年的 45 億美元，複合年成長率約為 9.6%。患者來源異質骨移植(PDX) 模型市場使用植入免疫力缺乏低下的小鼠的人類腫瘤組織來研究癌症生物學和評估治療效果。該模型保留了人類腫瘤的異質性，並為個人化醫療提供了見解。基因分析和數據分析的進步提高了模型的準確性和適用性，支持了癌症研究和藥物開發工作的市場發展。

市場概覽

受個人化醫療和轉化癌症研究需求日益成長的推動，患者來源異質骨移植(PDX) 模型市場正在強勁擴張。在癌症高發病率和對更有效、個人化治療策略的迫切需求的推動下，腫瘤學領域佔據了絕對領先地位。基因組分析技術的進步和精準醫療的日益重視進一步加強了這一領域的主導地位。罕見癌症模型和免疫腫瘤學 PDX 模型等新興子區隔因其能夠滿足未滿足的臨床需求和促進對腫瘤生物學的理解而越來越受到關注。這些子區隔預計將對市場產生重大影響，為癌症治療提供新的見解，並促進市場創新治療方法的發展。用於基因編輯的 CRISPR/Cas9 等先進技術的整合也有望為藥物發現和行銷提供更準確、更具代表性的模型，從而推動市場向前發展。

市場區隔
類型 血癌模型、固體癌模型
產品 小鼠模型、大鼠模型
服務 植入、體內藥物測試和腫瘤組織採集
科技 CRISPR/Cas9， RNA干擾
目的 臨床前藥物開發、生物標記分析、癌症研究
最終用戶 製藥公司、生物技術公司、學術和研究機構、受託研究機構
階段 發現/篩檢、臨床前試驗
成分 動物和腫瘤模型
過程 腫瘤移植、模型檢驗

患者來源異質骨移植(PDX) 模型市場主要由腫瘤學領域主導，反映了對個人化癌症研究和市場開發的高需求。這一趨勢的促進因素是 PDX 模型可以忠實地模擬人類腫瘤生物學並提高治療結果的精確度。從地理位置上看，北美佔據了大部分市場，這得益於其先進的醫療保健基礎設施和在研發方面的大量投資。另一方面，受醫療保健支出增加和研究舉措不斷增加的推動，亞太地區市場正在蓬勃發展。

在競爭和監管動態方面，Charles River Laboratories、The Jackson Laboratory 和 Crown Bioscience 等主要產業參與者正專注於策略聯盟和技術創新，以保持競爭優勢。北美和歐洲的監管環境不斷發展，制定了嚴格的指導方針，以確保 PDX 模型的合乎道德和有效使用。展望未來，在基因組技術的進步和個人化醫療日益受到重視的推動下，市場預計將經歷強勁成長。然而，倫理問題和PDX模型高成本等挑戰依然存在，生物技術和精準醫療的持續創新為市場擴張提供了機會。

主要趨勢和促進因素：

在個人化醫療和腫瘤學研究的推動下，患者來源異質骨移植(PDX) 模型市場正在經歷強勁成長。一個關鍵趨勢是藥物發現和開發中擴大採用 PDX 模型，這可以更好地預測人類對癌症治療的反應。此外，人工智慧和機器學習的融合正在增強數據分析和解釋，從而帶來更有效率、更有針對性的治療策略。

該市場的促進因素包括全球癌症盛行率的不斷上升以及對更有效治療方案的迫切需求。由於傳統癌症模型的局限性，研究人員正在轉向 PDX 模型來提供更多與臨床相關的見解。此外，政府和私人對癌症研究的資助增加也有助於推動市場發展。相關人員認知到 PDX 模型在推進藥物開發方面的價值。

為罕見和惡性癌症類型開發新型 PDX 模型有著巨大的機會，但現有模型還不夠完善。投資擴大其 PDX 模型庫和改進模型表徵的公司將獲得競爭優勢。此外，學術機構和製藥公司之間的合作將推動創新，從而創建更複雜、更具預測性的 PDX 模型，最終推動市場成長。

限制與挑戰：

患者異質骨移植(PDX) 模型市場目前正在克服幾個關鍵的市場限制和挑戰。一個主要障礙是開發和維護 PDX 模型的成本高昂，限制了小型研究機構和組織的使用。此外，在多次傳代過程中保持遺傳保真度的複雜性帶來了技術挑戰，可能會影響研究結果的可靠性。倫理問題也構成了重大障礙，因為在研究中使用動物模型繼續受到倡導團體的審查並影響監管格局。此外，建立 PDX 模型的漫長而複雜的過程可能會減慢研究時間表並阻礙尋求快速回報的潛在投資者。最後，PDX 模型的個人化特性需要大量的資源和時間，難以​​有效滿足不斷成長的需求，且市場面臨擴充性的限制。總的來說，這些因素阻礙了市場快速擴張和採用的潛力。

目錄

第1章 病患來源異質骨移植/PDX 模型市場概述

  • 研究目標
  • 患者來源異質骨移植/PDX 模型市場定義和範圍
  • 報告限制
  • 調查年份和貨幣
  • 調查方法

第2章執行摘要

第3章重要考察

第4章 人源異質骨移植/PDX 模型市場展望

  • 患者來源異質骨移植/PDX 模型市場細分
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 價值鏈分析
  • 4Ps模型
  • 安索夫矩陣

5. 病人來源異質骨移植/PDX 模型市場策略

  • 母市場分析
  • 供需分析
  • 消費者購買意向
  • 案例研究分析
  • 定價分析
  • 監管狀況
  • 供應鏈分析
  • 競爭產品分析
  • 近期動態

第6章 病人來源異質骨移植/PDX 模型市場規模

  • 患者來源異質骨移植/PDX 模型市場規模（按價值）
  • 患者來源異質骨移植/PDX 模型市場規模（按數量）

7. 病人來源異質骨移植/PDX 模型市場（按類型）

  • 市場概覽
  • 血癌模型
  • 固體癌模型
  • 其他

8. 病人來源異質骨移植/PDX 模型市場（按產品）

  • 市場概覽
  • 小鼠模型
  • 大鼠模型
  • 其他

9. 病人異質骨移植/PDX 模型市場（按服務）

  • 市場概覽
  • 移植
  • 體內藥物測試
  • 腫瘤組織採購
  • 其他

10. 病人來源異質骨移植/PDX 模型市場（依技術）

  • 市場概覽
  • CRISPR/Cas9
  • RNA干擾
  • 其他

第 11 章 患者異質骨移植/PDX 模型市場（按應用）

  • 市場概覽
  • 臨床前藥物開發
  • 生物標記分析
  • 癌症研究
  • 其他

12. 病患來源異質骨移植/PDX 模型市場（依最終使用者）

  • 市場概覽
  • 製藥公司
  • 生技公司
  • 學術和研究機構
  • 受託研究機構
  • 其他

13. 病人來源異質骨移植/PDX 模型市場（依階段）

  • 市場概覽
  • 發現與篩檢
  • 臨床前試驗
  • 其他

14. 病患來源異質骨移植/PDX 模型市場（按組件）

  • 市場概覽
  • 動物模型
  • 腫瘤模型
  • 其他

15. 病患來源異質骨移植/PDX 模型市場（依流程）

  • 市場概覽
  • 腫瘤植入
  • 模型驗證
  • 其他

16. 病患來源異質骨移植/PDX 模型市場（按地區）

  • 概述
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
    • 瑞典
    • 瑞士
    • 丹麥
    • 芬蘭
    • 俄羅斯
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 新加坡
    • 印尼
    • 台灣
    • 馬來西亞
    • 其他亞太地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他拉丁美洲
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 其他中東和非洲地區

第17章競爭格局

  • 概述
  • 市場佔有率分析
  • 主要企業定位
  • 衝突領導地圖
  • 供應商基準化分析
  • 發展策略基準化分析

第18章 公司簡介

  • Crown Bioscience
  • The Jackson Laboratory
  • Charles River Laboratories
  • Horizon Discovery
  • WuXi AppTec
  • Champion Oncology
  • Oncodesign
  • Xentech
  • EPO Berlin-Buch
  • Pharmatest Services
  • Shanghai LIDE Biotech
  • Aragen Bioscience
  • Biomodels
  • Living Tumor Laboratory
  • MI Bioresearch
  • Altasciences
  • Explora BioLabs
  • Biocytogen
  • Envigo
  • GenenDesign
簡介目錄
Product Code: GIS20433

Patient-Derived Xenograft/PDX Model Market is anticipated to expand from $1.8 billion in 2024 to $4.5 billion by 2034, growing at a CAGR of approximately 9.6%. The Patient-Derived Xenograft (PDX) Model Market involves the use of human tumor tissues implanted into immunodeficient mice to study cancer biology and evaluate therapeutic efficacy. This model preserves the heterogeneity of human tumors, offering insights into personalized medicine. Increasing cancer research and drug development efforts propel market growth, with advancements in genetic profiling and data analysis enhancing model precision and applicability.

Market Overview

The Patient-Derived Xenograft (PDX) Model Market is experiencing robust expansion, fueled by the increasing need for personalized medicine and translational cancer research. The oncology segment stands as the predominant leader, driven by the high prevalence of cancer and the urgent demand for more effective and tailored therapeutic strategies. This segment's dominance is further bolstered by technological advancements in genomic profiling and the growing emphasis on precision medicine. Emerging sub-segments, such as rare cancer models and immuno-oncology PDX models, are gaining traction due to their potential to address unmet clinical needs and enhance the understanding of tumor biology. These sub-segments are poised to significantly impact the market by offering novel insights into cancer treatment and fostering the development of innovative therapies. The integration of advanced technologies, such as CRISPR/Cas9 for gene editing, is also anticipated to propel the market forward, providing more accurate and representative models for drug discovery and development.

Market Segmentation
TypeHematological Cancer Models, Solid Tumor Models
ProductMice Models, Rat Models
ServicesImplantation and Engraftment, In Vivo Drug Testing, Tumor Tissue Procurement
TechnologyCRISPR/Cas9, RNA Interference
ApplicationPreclinical Drug Development, Biomarker Analysis, Oncology Research
End UserPharmaceutical Companies, Biotechnology Companies, Academic and Research Institutes, Contract Research Organizations
StageDiscovery and Screening, Preclinical Testing
ComponentAnimals, Tumor Models
ProcessTumor Implantation, Model Validation

The Patient-Derived Xenograft (PDX) Model Market is primarily dominated by the oncology segment, reflecting the high demand for personalized cancer research and drug development. This preference is attributed to the PDX model's ability to closely mimic human tumor biology, thereby enhancing the precision of therapeutic outcomes. Geographically, North America holds a significant portion of the market, driven by advanced healthcare infrastructure and substantial investments in R&D. Meanwhile, the Asia-Pacific region is witnessing a surge in market activity, fueled by increasing healthcare expenditure and growing research initiatives.

In terms of competitive and regulatory dynamics, key industry participants such as Charles River Laboratories, The Jackson Laboratory, and Crown Bioscience are intensifying their focus on strategic collaborations and technological innovations to maintain competitive advantage. Regulatory landscapes in North America and Europe continue to evolve, with stringent guidelines ensuring ethical and effective use of PDX models. Looking ahead, the market is poised for robust growth, propelled by advancements in genomic technologies and a rising emphasis on personalized medicine. However, challenges such as ethical concerns and the high cost of PDX models remain, yet the ongoing innovations in biotechnology and precision medicine present lucrative opportunities for market expansion.

Recent Developments:

The Patient-Derived Xenograft (PDX) Model Market has experienced noteworthy developments over the past three months. In a significant merger, BioXcell Therapeutics acquired CellPath Technologies, aiming to enhance their PDX model offerings and expand their global reach. Meanwhile, a strategic partnership between OncoGenomics and PharmaTech Solutions was announced, focusing on collaborative research to accelerate drug discovery using PDX models. Innovation continues as PDX Innovations launched a new line of genetically diverse PDX models, designed to improve precision medicine approaches in oncology. Regulatory advancements were made as the FDA introduced new guidelines to streamline the approval process for therapies developed using PDX models, potentially reducing time-to-market. On the financial front, VentureHealth invested $50 million in PDX Biotech, a company known for its cutting-edge PDX model development, to support its research and development initiatives. These events underscore the dynamic nature of the PDX model market, highlighting its critical role in advancing cancer research and therapeutics.

Key Trends and Drivers:

The Patient-Derived Xenograft (PDX) Model Market is experiencing robust growth driven by advancements in personalized medicine and oncology research. Key trends include the increasing adoption of PDX models for drug discovery and development, providing more accurate predictions of human responses to cancer therapies. The market is also witnessing the integration of artificial intelligence and machine learning, enhancing data analysis and interpretation, leading to more efficient and targeted treatment strategies.

Drivers of this market include the growing prevalence of cancer worldwide and the urgent need for more effective therapeutic options. The limitations of traditional cancer models are pushing researchers towards PDX models, which offer more clinically relevant insights. Additionally, the rise in government and private funding for cancer research is propelling market expansion, as stakeholders recognize the value of PDX models in accelerating drug development.

Opportunities abound in the development of novel PDX models for rare and aggressive cancer types, where existing models fall short. Companies investing in expanding their PDX model libraries and improving model characterization stand to gain a competitive edge. Furthermore, collaborations between academic institutions and pharmaceutical companies are fostering innovation, leading to the creation of more sophisticated and predictive PDX models, ultimately driving market growth.

Restraints and Challenges:

The Patient-Derived Xenograft (PDX) Model Market is currently navigating several key restraints and challenges. A significant obstacle is the high cost associated with developing and maintaining PDX models, which limits accessibility for smaller research entities and institutions. Additionally, the complexity of maintaining genetic fidelity over multiple passages presents a technical challenge, potentially affecting the reliability of research outcomes. Ethical concerns also pose a substantial barrier, as the use of animal models in research continues to face scrutiny from advocacy groups, influencing regulatory landscapes. Furthermore, the lengthy and intricate process of establishing PDX models can slow down research timelines, deterring potential investors seeking quicker returns. Lastly, the market faces limitations in scalability, as the personalized nature of PDX models demands significant resources and time, making it challenging to meet growing demand efficiently. These factors collectively impede the market's potential for rapid expansion and widespread adoption.

Key Companies:

Crown Bioscience, The Jackson Laboratory, Charles River Laboratories, Horizon Discovery, Wu Xi App Tec, Champion Oncology, Oncodesign, Xentech, EPO Berlin- Buch, Pharmatest Services, Shanghai LIDE Biotech, Aragen Bioscience, Biomodels, Living Tumor Laboratory, MI Bioresearch, Altasciences, Explora Bio Labs, Biocytogen, Envigo, Genen Design

Sources:

National Institutes of Health (NIH), European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA), National Cancer Institute (NCI), World Health Organization (WHO), American Association for Cancer Research (AACR), European Society for Medical Oncology (ESMO), Society for Laboratory Automation and Screening (SLAS), International Society for Stem Cell Research (ISSCR), American Society of Clinical Oncology (ASCO), International Cancer Research Partnership (ICRP), Cancer Research UK, National Center for Biotechnology Information (NCBI), International Agency for Research on Cancer (IARC), National Comprehensive Cancer Network (NCCN), Translational Research Cancer Centers Consortium (TRCCC), U.S. Department of Health and Human Services (HHS), European Association for Cancer Research (EACR), Federation of American Societies for Experimental Biology (FASEB), International Conference on Cancer Research and Targeted Therapy

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1: Patient-Derived Xenograft/PDX Model Market Overview

  • 1.1 Objectives of the Study
  • 1.2 Patient-Derived Xenograft/PDX Model Market Definition and Scope of the Report
  • 1.3 Report Limitations
  • 1.4 Years & Currency Considered in the Study
  • 1.5 Research Methodologies
    • 1.5.1 Secondary Research
    • 1.5.2 Primary Research
    • 1.5.3 Market Size Estimation: Top-Down Approach
    • 1.5.4 Market Size Estimation: Bottom-Up Approach
    • 1.5.5 Data Triangulation and Validation

2: Executive Summary

  • 2.1 Summary
  • 2.2 Key Opinion Leaders
  • 2.3 Key Highlights of the Market, by Type
  • 2.4 Key Highlights of the Market, by Product
  • 2.5 Key Highlights of the Market, by Services
  • 2.6 Key Highlights of the Market, by Technology
  • 2.7 Key Highlights of the Market, by Application
  • 2.8 Key Highlights of the Market, by End User
  • 2.9 Key Highlights of the Market, by Stage
  • 2.10 Key Highlights of the Market, by Component
  • 2.11 Key Highlights of the Market, by Process
  • 2.12 Key Highlights of the Market, by North America
  • 2.13 Key Highlights of the Market, by Europe
  • 2.14 Key Highlights of the Market, by Asia-Pacific
  • 2.15 Key Highlights of the Market, by Latin America
  • 2.16 Key Highlights of the Market, by Middle East
  • 2.17 Key Highlights of the Market, by Africa

3: Premium Insights on the Market

  • 3.1 Market Attractiveness Analysis, by Region
  • 3.2 Market Attractiveness Analysis, by Type
  • 3.3 Market Attractiveness Analysis, by Product
  • 3.4 Market Attractiveness Analysis, by Services
  • 3.5 Market Attractiveness Analysis, by Technology
  • 3.6 Market Attractiveness Analysis, by Application
  • 3.7 Market Attractiveness Analysis, by End User
  • 3.8 Market Attractiveness Analysis, by Stage
  • 3.9 Market Attractiveness Analysis, by Component
  • 3.10 Market Attractiveness Analysis, by Process
  • 3.11 Market Attractiveness Analysis, by North America
  • 3.12 Market Attractiveness Analysis, by Europe
  • 3.13 Market Attractiveness Analysis, by Asia-Pacific
  • 3.14 Market Attractiveness Analysis, by Latin America
  • 3.15 Market Attractiveness Analysis, by Middle East
  • 3.16 Market Attractiveness Analysis, by Africa

4: Patient-Derived Xenograft/PDX Model Market Outlook

  • 4.1 Patient-Derived Xenograft/PDX Model Market Segmentation
  • 4.2 Market Dynamics
    • 4.2.1 Market Drivers
    • 4.2.2 Market Trends
    • 4.2.3 Market Restraints
    • 4.2.4 Market Opportunities
  • 4.3 Porters Five Forces Analysis
    • 4.3.1 Threat of New Entrants
    • 4.3.2 Threat of Substitutes
    • 4.3.3 Bargaining Power of Buyers
    • 4.3.4 Bargaining Power of Supplier
    • 4.3.5 Competitive Rivalry
  • 4.4 PESTLE Analysis
  • 4.5 Value Chain Analysis
  • 4.6 4Ps Model
  • 4.7 ANSOFF Matrix

5: Patient-Derived Xenograft/PDX Model Market Strategy

  • 5.1 Parent Market Analysis
  • 5.2 Supply-Demand Analysis
  • 5.3 Consumer Buying Interest
  • 5.4 Case Study Analysis
  • 5.5 Pricing Analysis
  • 5.6 Regulatory Landscape
  • 5.7 Supply Chain Analysis
  • 5.8 Competition Product Analysis
  • 5.9 Recent Developments

6: Patient-Derived Xenograft/PDX Model Market Size

  • 6.1 Patient-Derived Xenograft/PDX Model Market Size, by Value
  • 6.2 Patient-Derived Xenograft/PDX Model Market Size, by Volume

7: Patient-Derived Xenograft/PDX Model Market, by Type

  • 7.1 Market Overview
  • 7.2 Hematological Cancer Models
    • 7.2.1 Key Market Trends & Opportunity Analysis
    • 7.2.2 Market Size and Forecast, by Region
  • 7.3 Solid Tumor Models
    • 7.3.1 Key Market Trends & Opportunity Analysis
    • 7.3.2 Market Size and Forecast, by Region
  • 7.4 Others
    • 7.4.1 Key Market Trends & Opportunity Analysis
    • 7.4.2 Market Size and Forecast, by Region

8: Patient-Derived Xenograft/PDX Model Market, by Product

  • 8.1 Market Overview
  • 8.2 Mice Models
    • 8.2.1 Key Market Trends & Opportunity Analysis
    • 8.2.2 Market Size and Forecast, by Region
  • 8.3 Rat Models
    • 8.3.1 Key Market Trends & Opportunity Analysis
    • 8.3.2 Market Size and Forecast, by Region
  • 8.4 Others
    • 8.4.1 Key Market Trends & Opportunity Analysis
    • 8.4.2 Market Size and Forecast, by Region

9: Patient-Derived Xenograft/PDX Model Market, by Services

  • 9.1 Market Overview
  • 9.2 Implantation and Engraftment
    • 9.2.1 Key Market Trends & Opportunity Analysis
    • 9.2.2 Market Size and Forecast, by Region
  • 9.3 In Vivo Drug Testing
    • 9.3.1 Key Market Trends & Opportunity Analysis
    • 9.3.2 Market Size and Forecast, by Region
  • 9.4 Tumor Tissue Procurement
    • 9.4.1 Key Market Trends & Opportunity Analysis
    • 9.4.2 Market Size and Forecast, by Region
  • 9.5 Others
    • 9.5.1 Key Market Trends & Opportunity Analysis
    • 9.5.2 Market Size and Forecast, by Region

10: Patient-Derived Xenograft/PDX Model Market, by Technology

  • 10.1 Market Overview
  • 10.2 CRISPR/Cas9
    • 10.2.1 Key Market Trends & Opportunity Analysis
    • 10.2.2 Market Size and Forecast, by Region
  • 10.3 RNA Interference
    • 10.3.1 Key Market Trends & Opportunity Analysis
    • 10.3.2 Market Size and Forecast, by Region
  • 10.4 Others
    • 10.4.1 Key Market Trends & Opportunity Analysis
    • 10.4.2 Market Size and Forecast, by Region

11: Patient-Derived Xenograft/PDX Model Market, by Application

  • 11.1 Market Overview
  • 11.2 Preclinical Drug Development
    • 11.2.1 Key Market Trends & Opportunity Analysis
    • 11.2.2 Market Size and Forecast, by Region
  • 11.3 Biomarker Analysis
    • 11.3.1 Key Market Trends & Opportunity Analysis
    • 11.3.2 Market Size and Forecast, by Region
  • 11.4 Oncology Research
    • 11.4.1 Key Market Trends & Opportunity Analysis
    • 11.4.2 Market Size and Forecast, by Region
  • 11.5 Others
    • 11.5.1 Key Market Trends & Opportunity Analysis
    • 11.5.2 Market Size and Forecast, by Region

12: Patient-Derived Xenograft/PDX Model Market, by End User

  • 12.1 Market Overview
  • 12.2 Pharmaceutical Companies
    • 12.2.1 Key Market Trends & Opportunity Analysis
    • 12.2.2 Market Size and Forecast, by Region
  • 12.3 Biotechnology Companies
    • 12.3.1 Key Market Trends & Opportunity Analysis
    • 12.3.2 Market Size and Forecast, by Region
  • 12.4 Academic and Research Institutes
    • 12.4.1 Key Market Trends & Opportunity Analysis
    • 12.4.2 Market Size and Forecast, by Region
  • 12.5 Contract Research Organizations
    • 12.5.1 Key Market Trends & Opportunity Analysis
    • 12.5.2 Market Size and Forecast, by Region
  • 12.6 Others
    • 12.6.1 Key Market Trends & Opportunity Analysis
    • 12.6.2 Market Size and Forecast, by Region

13: Patient-Derived Xenograft/PDX Model Market, by Stage

  • 13.1 Market Overview
  • 13.2 Discovery and Screening
    • 13.2.1 Key Market Trends & Opportunity Analysis
    • 13.2.2 Market Size and Forecast, by Region
  • 13.3 Preclinical Testing
    • 13.3.1 Key Market Trends & Opportunity Analysis
    • 13.3.2 Market Size and Forecast, by Region
  • 13.4 Others
    • 13.4.1 Key Market Trends & Opportunity Analysis
    • 13.4.2 Market Size and Forecast, by Region

14: Patient-Derived Xenograft/PDX Model Market, by Component

  • 14.1 Market Overview
  • 14.2 Animals
    • 14.2.1 Key Market Trends & Opportunity Analysis
    • 14.2.2 Market Size and Forecast, by Region
  • 14.3 Tumor Models
    • 14.3.1 Key Market Trends & Opportunity Analysis
    • 14.3.2 Market Size and Forecast, by Region
  • 14.4 Others
    • 14.4.1 Key Market Trends & Opportunity Analysis
    • 14.4.2 Market Size and Forecast, by Region

15: Patient-Derived Xenograft/PDX Model Market, by Process

  • 15.1 Market Overview
  • 15.2 Tumor Implantation
    • 15.2.1 Key Market Trends & Opportunity Analysis
    • 15.2.2 Market Size and Forecast, by Region
  • 15.3 Model Validation
    • 15.3.1 Key Market Trends & Opportunity Analysis
    • 15.3.2 Market Size and Forecast, by Region
  • 15.4 Others
    • 15.4.1 Key Market Trends & Opportunity Analysis
    • 15.4.2 Market Size and Forecast, by Region

16: Patient-Derived Xenograft/PDX Model Market, by Region

  • 16.1 Overview
  • 16.2 North America
    • 16.2.1 Key Market Trends and Opportunities
    • 16.2.2 North America Market Size and Forecast, by Type
    • 16.2.3 North America Market Size and Forecast, by Product
    • 16.2.4 North America Market Size and Forecast, by Services
    • 16.2.5 North America Market Size and Forecast, by Technology
    • 16.2.6 North America Market Size and Forecast, by Application
    • 16.2.7 North America Market Size and Forecast, by End User
    • 16.2.8 North America Market Size and Forecast, by Stage
    • 16.2.9 North America Market Size and Forecast, by Component
    • 16.2.10 North America Market Size and Forecast, by Process
    • 16.2.11 North America Market Size and Forecast, by Country
    • 16.2.12 United States
      • 16.2.9.1 United States Market Size and Forecast, by Type
      • 16.2.9.2 United States Market Size and Forecast, by Product
      • 16.2.9.3 United States Market Size and Forecast, by Services
      • 16.2.9.4 United States Market Size and Forecast, by Technology
      • 16.2.9.5 United States Market Size and Forecast, by Application
      • 16.2.9.6 United States Market Size and Forecast, by End User
      • 16.2.9.7 United States Market Size and Forecast, by Stage
      • 16.2.9.8 United States Market Size and Forecast, by Component
      • 16.2.9.9 United States Market Size and Forecast, by Process
      • 16.2.9.10 Local Competition Analysis
      • 16.2.9.11 Local Market Analysis
    • 16.2.1 Canada
      • 16.2.10.1 Canada Market Size and Forecast, by Type
      • 16.2.10.2 Canada Market Size and Forecast, by Product
      • 16.2.10.3 Canada Market Size and Forecast, by Services
      • 16.2.10.4 Canada Market Size and Forecast, by Technology
      • 16.2.10.5 Canada Market Size and Forecast, by Application
      • 16.2.10.6 Canada Market Size and Forecast, by End User
      • 16.2.10.7 Canada Market Size and Forecast, by Stage
      • 16.2.10.8 Canada Market Size and Forecast, by Component
      • 16.2.10.9 Canada Market Size and Forecast, by Process
      • 16.2.10.10 Local Competition Analysis
      • 16.2.10.11 Local Market Analysis
  • 16.1 Europe
    • 16.3.1 Key Market Trends and Opportunities
    • 16.3.2 Europe Market Size and Forecast, by Type
    • 16.3.3 Europe Market Size and Forecast, by Product
    • 16.3.4 Europe Market Size and Forecast, by Services
    • 16.3.5 Europe Market Size and Forecast, by Technology
    • 16.3.6 Europe Market Size and Forecast, by Application
    • 16.3.7 Europe Market Size and Forecast, by End User
    • 16.3.8 Europe Market Size and Forecast, by Stage
    • 16.3.9 Europe Market Size and Forecast, by Component
    • 16.3.10 Europe Market Size and Forecast, by Process
    • 16.3.11 Europe Market Size and Forecast, by Country
    • 16.3.12 United Kingdom
      • 16.3.9.1 United Kingdom Market Size and Forecast, by Type
      • 16.3.9.2 United Kingdom Market Size and Forecast, by Product
      • 16.3.9.3 United Kingdom Market Size and Forecast, by Services
      • 16.3.9.4 United Kingdom Market Size and Forecast, by Technology
      • 16.3.9.5 United Kingdom Market Size and Forecast, by Application
      • 16.3.9.6 United Kingdom Market Size and Forecast, by End User
      • 16.3.9.7 United Kingdom Market Size and Forecast, by Stage
      • 16.3.9.8 United Kingdom Market Size and Forecast, by Component
      • 16.3.9.9 United Kingdom Market Size and Forecast, by Process
      • 16.3.9.10 Local Competition Analysis
      • 16.3.9.11 Local Market Analysis
    • 16.3.1 Germany
      • 16.3.10.1 Germany Market Size and Forecast, by Type
      • 16.3.10.2 Germany Market Size and Forecast, by Product
      • 16.3.10.3 Germany Market Size and Forecast, by Services
      • 16.3.10.4 Germany Market Size and Forecast, by Technology
      • 16.3.10.5 Germany Market Size and Forecast, by Application
      • 16.3.10.6 Germany Market Size and Forecast, by End User
      • 16.3.10.7 Germany Market Size and Forecast, by Stage
      • 16.3.10.8 Germany Market Size and Forecast, by Component
      • 16.3.10.9 Germany Market Size and Forecast, by Process
      • 16.3.10.10 Local Competition Analysis
      • 16.3.10.11 Local Market Analysis
    • 16.3.1 France
      • 16.3.11.1 France Market Size and Forecast, by Type
      • 16.3.11.2 France Market Size and Forecast, by Product
      • 16.3.11.3 France Market Size and Forecast, by Services
      • 16.3.11.4 France Market Size and Forecast, by Technology
      • 16.3.11.5 France Market Size and Forecast, by Application
      • 16.3.11.6 France Market Size and Forecast, by End User
      • 16.3.11.7 France Market Size and Forecast, by Stage
      • 16.3.11.8 France Market Size and Forecast, by Component
      • 16.3.11.9 France Market Size and Forecast, by Process
      • 16.3.11.10 Local Competition Analysis
      • 16.3.11.11 Local Market Analysis
    • 16.3.1 Spain
      • 16.3.12.1 Spain Market Size and Forecast, by Type
      • 16.3.12.2 Spain Market Size and Forecast, by Product
      • 16.3.12.3 Spain Market Size and Forecast, by Services
      • 16.3.12.4 Spain Market Size and Forecast, by Technology
      • 16.3.12.5 Spain Market Size and Forecast, by Application
      • 16.3.12.6 Spain Market Size and Forecast, by End User
      • 16.3.12.7 Spain Market Size and Forecast, by Stage
      • 16.3.12.8 Spain Market Size and Forecast, by Component
      • 16.3.12.9 Spain Market Size and Forecast, by Process
      • 16.3.12.10 Local Competition Analysis
      • 16.3.12.11 Local Market Analysis
    • 16.3.1 Italy
      • 16.3.13.1 Italy Market Size and Forecast, by Type
      • 16.3.13.2 Italy Market Size and Forecast, by Product
      • 16.3.13.3 Italy Market Size and Forecast, by Services
      • 16.3.13.4 Italy Market Size and Forecast, by Technology
      • 16.3.13.5 Italy Market Size and Forecast, by Application
      • 16.3.13.6 Italy Market Size and Forecast, by End User
      • 16.3.13.7 Italy Market Size and Forecast, by Stage
      • 16.3.13.8 Italy Market Size and Forecast, by Component
      • 16.3.13.9 Italy Market Size and Forecast, by Process
      • 16.3.13.10 Local Competition Analysis
      • 16.3.13.11 Local Market Analysis
    • 16.3.1 Netherlands
      • 16.3.14.1 Netherlands Market Size and Forecast, by Type
      • 16.3.14.2 Netherlands Market Size and Forecast, by Product
      • 16.3.14.3 Netherlands Market Size and Forecast, by Services
      • 16.3.14.4 Netherlands Market Size and Forecast, by Technology
      • 16.3.14.5 Netherlands Market Size and Forecast, by Application
      • 16.3.14.6 Netherlands Market Size and Forecast, by End User
      • 16.3.14.7 Netherlands Market Size and Forecast, by Stage
      • 16.3.14.8 Netherlands Market Size and Forecast, by Component
      • 16.3.14.9 Netherlands Market Size and Forecast, by Process
      • 16.3.14.10 Local Competition Analysis
      • 16.3.14.11 Local Market Analysis
    • 16.3.1 Sweden
      • 16.3.15.1 Sweden Market Size and Forecast, by Type
      • 16.3.15.2 Sweden Market Size and Forecast, by Product
      • 16.3.15.3 Sweden Market Size and Forecast, by Services
      • 16.3.15.4 Sweden Market Size and Forecast, by Technology
      • 16.3.15.5 Sweden Market Size and Forecast, by Application
      • 16.3.15.6 Sweden Market Size and Forecast, by End User
      • 16.3.15.7 Sweden Market Size and Forecast, by Stage
      • 16.3.15.8 Sweden Market Size and Forecast, by Component
      • 16.3.15.9 Sweden Market Size and Forecast, by Process
      • 16.3.15.10 Local Competition Analysis
      • 16.3.15.11 Local Market Analysis
    • 16.3.1 Switzerland
      • 16.3.16.1 Switzerland Market Size and Forecast, by Type
      • 16.3.16.2 Switzerland Market Size and Forecast, by Product
      • 16.3.16.3 Switzerland Market Size and Forecast, by Services
      • 16.3.16.4 Switzerland Market Size and Forecast, by Technology
      • 16.3.16.5 Switzerland Market Size and Forecast, by Application
      • 16.3.16.6 Switzerland Market Size and Forecast, by End User
      • 16.3.16.7 Switzerland Market Size and Forecast, by Stage
      • 16.3.16.8 Switzerland Market Size and Forecast, by Component
      • 16.3.16.9 Switzerland Market Size and Forecast, by Process
      • 16.3.16.10 Local Competition Analysis
      • 16.3.16.11 Local Market Analysis
    • 16.3.1 Denmark
      • 16.3.17.1 Denmark Market Size and Forecast, by Type
      • 16.3.17.2 Denmark Market Size and Forecast, by Product
      • 16.3.17.3 Denmark Market Size and Forecast, by Services
      • 16.3.17.4 Denmark Market Size and Forecast, by Technology
      • 16.3.17.5 Denmark Market Size and Forecast, by Application
      • 16.3.17.6 Denmark Market Size and Forecast, by End User
      • 16.3.17.7 Denmark Market Size and Forecast, by Stage
      • 16.3.17.8 Denmark Market Size and Forecast, by Component
      • 16.3.17.9 Denmark Market Size and Forecast, by Process
      • 16.3.17.10 Local Competition Analysis
      • 16.3.17.11 Local Market Analysis
    • 16.3.1 Finland
      • 16.3.18.1 Finland Market Size and Forecast, by Type
      • 16.3.18.2 Finland Market Size and Forecast, by Product
      • 16.3.18.3 Finland Market Size and Forecast, by Services
      • 16.3.18.4 Finland Market Size and Forecast, by Technology
      • 16.3.18.5 Finland Market Size and Forecast, by Application
      • 16.3.18.6 Finland Market Size and Forecast, by End User
      • 16.3.18.7 Finland Market Size and Forecast, by Stage
      • 16.3.18.8 Finland Market Size and Forecast, by Component
      • 16.3.18.9 Finland Market Size and Forecast, by Process
      • 16.3.18.10 Local Competition Analysis
      • 16.3.18.11 Local Market Analysis
    • 16.3.1 Russia
      • 16.3.19.1 Russia Market Size and Forecast, by Type
      • 16.3.19.2 Russia Market Size and Forecast, by Product
      • 16.3.19.3 Russia Market Size and Forecast, by Services
      • 16.3.19.4 Russia Market Size and Forecast, by Technology
      • 16.3.19.5 Russia Market Size and Forecast, by Application
      • 16.3.19.6 Russia Market Size and Forecast, by End User
      • 16.3.19.7 Russia Market Size and Forecast, by Stage
      • 16.3.19.8 Russia Market Size and Forecast, by Component
      • 16.3.19.9 Russia Market Size and Forecast, by Process
      • 16.3.19.10 Local Competition Analysis
      • 16.3.19.11 Local Market Analysis
    • 16.3.1 Rest of Europe
      • 16.3.20.1 Rest of Europe Market Size and Forecast, by Type
      • 16.3.20.2 Rest of Europe Market Size and Forecast, by Product
      • 16.3.20.3 Rest of Europe Market Size and Forecast, by Services
      • 16.3.20.4 Rest of Europe Market Size and Forecast, by Technology
      • 16.3.20.5 Rest of Europe Market Size and Forecast, by Application
      • 16.3.20.6 Rest of Europe Market Size and Forecast, by End User
      • 16.3.20.7 Rest of Europe Market Size and Forecast, by Stage
      • 16.3.20.8 Rest of Europe Market Size and Forecast, by Component
      • 16.3.20.9 Rest of Europe Market Size and Forecast, by Process
      • 16.3.20.10 Local Competition Analysis
      • 16.3.20.11 Local Market Analysis
  • 16.1 Asia-Pacific
    • 16.4.1 Key Market Trends and Opportunities
    • 16.4.2 Asia-Pacific Market Size and Forecast, by Type
    • 16.4.3 Asia-Pacific Market Size and Forecast, by Product
    • 16.4.4 Asia-Pacific Market Size and Forecast, by Services
    • 16.4.5 Asia-Pacific Market Size and Forecast, by Technology
    • 16.4.6 Asia-Pacific Market Size and Forecast, by Application
    • 16.4.7 Asia-Pacific Market Size and Forecast, by End User
    • 16.4.8 Asia-Pacific Market Size and Forecast, by Stage
    • 16.4.9 Asia-Pacific Market Size and Forecast, by Component
    • 16.4.10 Asia-Pacific Market Size and Forecast, by Process
    • 16.4.11 Asia-Pacific Market Size and Forecast, by Country
    • 16.4.12 China
      • 16.4.9.1 China Market Size and Forecast, by Type
      • 16.4.9.2 China Market Size and Forecast, by Product
      • 16.4.9.3 China Market Size and Forecast, by Services
      • 16.4.9.4 China Market Size and Forecast, by Technology
      • 16.4.9.5 China Market Size and Forecast, by Application
      • 16.4.9.6 China Market Size and Forecast, by End User
      • 16.4.9.7 China Market Size and Forecast, by Stage
      • 16.4.9.8 China Market Size and Forecast, by Component
      • 16.4.9.9 China Market Size and Forecast, by Process
      • 16.4.9.10 Local Competition Analysis
      • 16.4.9.11 Local Market Analysis
    • 16.4.1 India
      • 16.4.10.1 India Market Size and Forecast, by Type
      • 16.4.10.2 India Market Size and Forecast, by Product
      • 16.4.10.3 India Market Size and Forecast, by Services
      • 16.4.10.4 India Market Size and Forecast, by Technology
      • 16.4.10.5 India Market Size and Forecast, by Application
      • 16.4.10.6 India Market Size and Forecast, by End User
      • 16.4.10.7 India Market Size and Forecast, by Stage
      • 16.4.10.8 India Market Size and Forecast, by Component
      • 16.4.10.9 India Market Size and Forecast, by Process
      • 16.4.10.10 Local Competition Analysis
      • 16.4.10.11 Local Market Analysis
    • 16.4.1 Japan
      • 16.4.11.1 Japan Market Size and Forecast, by Type
      • 16.4.11.2 Japan Market Size and Forecast, by Product
      • 16.4.11.3 Japan Market Size and Forecast, by Services
      • 16.4.11.4 Japan Market Size and Forecast, by Technology
      • 16.4.11.5 Japan Market Size and Forecast, by Application
      • 16.4.11.6 Japan Market Size and Forecast, by End User
      • 16.4.11.7 Japan Market Size and Forecast, by Stage
      • 16.4.11.8 Japan Market Size and Forecast, by Component
      • 16.4.11.9 Japan Market Size and Forecast, by Process
      • 16.4.11.10 Local Competition Analysis
      • 16.4.11.11 Local Market Analysis
    • 16.4.1 South Korea
      • 16.4.12.1 South Korea Market Size and Forecast, by Type
      • 16.4.12.2 South Korea Market Size and Forecast, by Product
      • 16.4.12.3 South Korea Market Size and Forecast, by Services
      • 16.4.12.4 South Korea Market Size and Forecast, by Technology
      • 16.4.12.5 South Korea Market Size and Forecast, by Application
      • 16.4.12.6 South Korea Market Size and Forecast, by End User
      • 16.4.12.7 South Korea Market Size and Forecast, by Stage
      • 16.4.12.8 South Korea Market Size and Forecast, by Component
      • 16.4.12.9 South Korea Market Size and Forecast, by Process
      • 16.4.12.10 Local Competition Analysis
      • 16.4.12.11 Local Market Analysis
    • 16.4.1 Australia
      • 16.4.13.1 Australia Market Size and Forecast, by Type
      • 16.4.13.2 Australia Market Size and Forecast, by Product
      • 16.4.13.3 Australia Market Size and Forecast, by Services
      • 16.4.13.4 Australia Market Size and Forecast, by Technology
      • 16.4.13.5 Australia Market Size and Forecast, by Application
      • 16.4.13.6 Australia Market Size and Forecast, by End User
      • 16.4.13.7 Australia Market Size and Forecast, by Stage
      • 16.4.13.8 Australia Market Size and Forecast, by Component
      • 16.4.13.9 Australia Market Size and Forecast, by Process
      • 16.4.13.10 Local Competition Analysis
      • 16.4.13.11 Local Market Analysis
    • 16.4.1 Singapore
      • 16.4.14.1 Singapore Market Size and Forecast, by Type
      • 16.4.14.2 Singapore Market Size and Forecast, by Product
      • 16.4.14.3 Singapore Market Size and Forecast, by Services
      • 16.4.14.4 Singapore Market Size and Forecast, by Technology
      • 16.4.14.5 Singapore Market Size and Forecast, by Application
      • 16.4.14.6 Singapore Market Size and Forecast, by End User
      • 16.4.14.7 Singapore Market Size and Forecast, by Stage
      • 16.4.14.8 Singapore Market Size and Forecast, by Component
      • 16.4.14.9 Singapore Market Size and Forecast, by Process
      • 16.4.14.10 Local Competition Analysis
      • 16.4.14.11 Local Market Analysis
    • 16.4.1 Indonesia
      • 16.4.15.1 Indonesia Market Size and Forecast, by Type
      • 16.4.15.2 Indonesia Market Size and Forecast, by Product
      • 16.4.15.3 Indonesia Market Size and Forecast, by Services
      • 16.4.15.4 Indonesia Market Size and Forecast, by Technology
      • 16.4.15.5 Indonesia Market Size and Forecast, by Application
      • 16.4.15.6 Indonesia Market Size and Forecast, by End User
      • 16.4.15.7 Indonesia Market Size and Forecast, by Stage
      • 16.4.15.8 Indonesia Market Size and Forecast, by Component
      • 16.4.15.9 Indonesia Market Size and Forecast, by Process
      • 16.4.15.10 Local Competition Analysis
      • 16.4.15.11 Local Market Analysis
    • 16.4.1 Taiwan
      • 16.4.16.1 Taiwan Market Size and Forecast, by Type
      • 16.4.16.2 Taiwan Market Size and Forecast, by Product
      • 16.4.16.3 Taiwan Market Size and Forecast, by Services
      • 16.4.16.4 Taiwan Market Size and Forecast, by Technology
      • 16.4.16.5 Taiwan Market Size and Forecast, by Application
      • 16.4.16.6 Taiwan Market Size and Forecast, by End User
      • 16.4.16.7 Taiwan Market Size and Forecast, by Stage
      • 16.4.16.8 Taiwan Market Size and Forecast, by Component
      • 16.4.16.9 Taiwan Market Size and Forecast, by Process
      • 16.4.16.10 Local Competition Analysis
      • 16.4.16.11 Local Market Analysis
    • 16.4.1 Malaysia
      • 16.4.17.1 Malaysia Market Size and Forecast, by Type
      • 16.4.17.2 Malaysia Market Size and Forecast, by Product
      • 16.4.17.3 Malaysia Market Size and Forecast, by Services
      • 16.4.17.4 Malaysia Market Size and Forecast, by Technology
      • 16.4.17.5 Malaysia Market Size and Forecast, by Application
      • 16.4.17.6 Malaysia Market Size and Forecast, by End User
      • 16.4.17.7 Malaysia Market Size and Forecast, by Stage
      • 16.4.17.8 Malaysia Market Size and Forecast, by Component
      • 16.4.17.9 Malaysia Market Size and Forecast, by Process
      • 16.4.17.10 Local Competition Analysis
      • 16.4.17.11 Local Market Analysis
    • 16.4.1 Rest of Asia-Pacific
      • 16.4.18.1 Rest of Asia-Pacific Market Size and Forecast, by Type
      • 16.4.18.2 Rest of Asia-Pacific Market Size and Forecast, by Product
      • 16.4.18.3 Rest of Asia-Pacific Market Size and Forecast, by Services
      • 16.4.18.4 Rest of Asia-Pacific Market Size and Forecast, by Technology
      • 16.4.18.5 Rest of Asia-Pacific Market Size and Forecast, by Application
      • 16.4.18.6 Rest of Asia-Pacific Market Size and Forecast, by End User
      • 16.4.18.7 Rest of Asia-Pacific Market Size and Forecast, by Stage
      • 16.4.18.8 Rest of Asia-Pacific Market Size and Forecast, by Component
      • 16.4.18.9 Rest of Asia-Pacific Market Size and Forecast, by Process
      • 16.4.18.10 Local Competition Analysis
      • 16.4.18.11 Local Market Analysis
  • 16.1 Latin America
    • 16.5.1 Key Market Trends and Opportunities
    • 16.5.2 Latin America Market Size and Forecast, by Type
    • 16.5.3 Latin America Market Size and Forecast, by Product
    • 16.5.4 Latin America Market Size and Forecast, by Services
    • 16.5.5 Latin America Market Size and Forecast, by Technology
    • 16.5.6 Latin America Market Size and Forecast, by Application
    • 16.5.7 Latin America Market Size and Forecast, by End User
    • 16.5.8 Latin America Market Size and Forecast, by Stage
    • 16.5.9 Latin America Market Size and Forecast, by Component
    • 16.5.10 Latin America Market Size and Forecast, by Process
    • 16.5.11 Latin America Market Size and Forecast, by Country
    • 16.5.12 Brazil
      • 16.5.9.1 Brazil Market Size and Forecast, by Type
      • 16.5.9.2 Brazil Market Size and Forecast, by Product
      • 16.5.9.3 Brazil Market Size and Forecast, by Services
      • 16.5.9.4 Brazil Market Size and Forecast, by Technology
      • 16.5.9.5 Brazil Market Size and Forecast, by Application
      • 16.5.9.6 Brazil Market Size and Forecast, by End User
      • 16.5.9.7 Brazil Market Size and Forecast, by Stage
      • 16.5.9.8 Brazil Market Size and Forecast, by Component
      • 16.5.9.9 Brazil Market Size and Forecast, by Process
      • 16.5.9.10 Local Competition Analysis
      • 16.5.9.11 Local Market Analysis
    • 16.5.1 Mexico
      • 16.5.10.1 Mexico Market Size and Forecast, by Type
      • 16.5.10.2 Mexico Market Size and Forecast, by Product
      • 16.5.10.3 Mexico Market Size and Forecast, by Services
      • 16.5.10.4 Mexico Market Size and Forecast, by Technology
      • 16.5.10.5 Mexico Market Size and Forecast, by Application
      • 16.5.10.6 Mexico Market Size and Forecast, by End User
      • 16.5.10.7 Mexico Market Size and Forecast, by Stage
      • 16.5.10.8 Mexico Market Size and Forecast, by Component
      • 16.5.10.9 Mexico Market Size and Forecast, by Process
      • 16.5.10.10 Local Competition Analysis
      • 16.5.10.11 Local Market Analysis
    • 16.5.1 Argentina
      • 16.5.11.1 Argentina Market Size and Forecast, by Type
      • 16.5.11.2 Argentina Market Size and Forecast, by Product
      • 16.5.11.3 Argentina Market Size and Forecast, by Services
      • 16.5.11.4 Argentina Market Size and Forecast, by Technology
      • 16.5.11.5 Argentina Market Size and Forecast, by Application
      • 16.5.11.6 Argentina Market Size and Forecast, by End User
      • 16.5.11.7 Argentina Market Size and Forecast, by Stage
      • 16.5.11.8 Argentina Market Size and Forecast, by Component
      • 16.5.11.9 Argentina Market Size and Forecast, by Process
      • 16.5.11.10 Local Competition Analysis
      • 16.5.11.11 Local Market Analysis
    • 16.5.1 Rest of Latin America
      • 16.5.12.1 Rest of Latin America Market Size and Forecast, by Type
      • 16.5.12.2 Rest of Latin America Market Size and Forecast, by Product
      • 16.5.12.3 Rest of Latin America Market Size and Forecast, by Services
      • 16.5.12.4 Rest of Latin America Market Size and Forecast, by Technology
      • 16.5.12.5 Rest of Latin America Market Size and Forecast, by Application
      • 16.5.12.6 Rest of Latin America Market Size and Forecast, by End User
      • 16.5.12.7 Rest of Latin America Market Size and Forecast, by Stage
      • 16.5.12.8 Rest of Latin America Market Size and Forecast, by Component
      • 16.5.12.9 Rest of Latin America Market Size and Forecast, by Process
      • 16.5.12.10 Local Competition Analysis
      • 16.5.12.11 Local Market Analysis
  • 16.1 Middle East and Africa
    • 16.6.1 Key Market Trends and Opportunities
    • 16.6.2 Middle East and Africa Market Size and Forecast, by Type
    • 16.6.3 Middle East and Africa Market Size and Forecast, by Product
    • 16.6.4 Middle East and Africa Market Size and Forecast, by Services
    • 16.6.5 Middle East and Africa Market Size and Forecast, by Technology
    • 16.6.6 Middle East and Africa Market Size and Forecast, by Application
    • 16.6.7 Middle East and Africa Market Size and Forecast, by End User
    • 16.6.8 Middle East and Africa Market Size and Forecast, by Stage
    • 16.6.9 Middle East and Africa Market Size and Forecast, by Component
    • 16.6.10 Middle East and Africa Market Size and Forecast, by Process
    • 16.6.11 Middle East and Africa Market Size and Forecast, by Country
    • 16.6.12 Saudi Arabia
      • 16.6.9.1 Saudi Arabia Market Size and Forecast, by Type
      • 16.6.9.2 Saudi Arabia Market Size and Forecast, by Product
      • 16.6.9.3 Saudi Arabia Market Size and Forecast, by Services
      • 16.6.9.4 Saudi Arabia Market Size and Forecast, by Technology
      • 16.6.9.5 Saudi Arabia Market Size and Forecast, by Application
      • 16.6.9.6 Saudi Arabia Market Size and Forecast, by End User
      • 16.6.9.7 Saudi Arabia Market Size and Forecast, by Stage
      • 16.6.9.8 Saudi Arabia Market Size and Forecast, by Component
      • 16.6.9.9 Saudi Arabia Market Size and Forecast, by Process
      • 16.6.9.10 Local Competition Analysis
      • 16.6.9.11 Local Market Analysis
    • 16.6.1 UAE
      • 16.6.10.1 UAE Market Size and Forecast, by Type
      • 16.6.10.2 UAE Market Size and Forecast, by Product
      • 16.6.10.3 UAE Market Size and Forecast, by Services
      • 16.6.10.4 UAE Market Size and Forecast, by Technology
      • 16.6.10.5 UAE Market Size and Forecast, by Application
      • 16.6.10.6 UAE Market Size and Forecast, by End User
      • 16.6.10.7 UAE Market Size and Forecast, by Stage
      • 16.6.10.8 UAE Market Size and Forecast, by Component
      • 16.6.10.9 UAE Market Size and Forecast, by Process
      • 16.6.10.10 Local Competition Analysis
      • 16.6.10.11 Local Market Analysis
    • 16.6.1 South Africa
      • 16.6.11.1 South Africa Market Size and Forecast, by Type
      • 16.6.11.2 South Africa Market Size and Forecast, by Product
      • 16.6.11.3 South Africa Market Size and Forecast, by Services
      • 16.6.11.4 South Africa Market Size and Forecast, by Technology
      • 16.6.11.5 South Africa Market Size and Forecast, by Application
      • 16.6.11.6 South Africa Market Size and Forecast, by End User
      • 16.6.11.7 South Africa Market Size and Forecast, by Stage
      • 16.6.11.8 South Africa Market Size and Forecast, by Component
      • 16.6.11.9 South Africa Market Size and Forecast, by Process
      • 16.6.11.10 Local Competition Analysis
      • 16.6.11.11 Local Market Analysis
    • 16.6.1 Rest of MEA
      • 16.6.12.1 Rest of MEA Market Size and Forecast, by Type
      • 16.6.12.2 Rest of MEA Market Size and Forecast, by Product
      • 16.6.12.3 Rest of MEA Market Size and Forecast, by Services
      • 16.6.12.4 Rest of MEA Market Size and Forecast, by Technology
      • 16.6.12.5 Rest of MEA Market Size and Forecast, by Application
      • 16.6.12.6 Rest of MEA Market Size and Forecast, by End User
      • 16.6.12.7 Rest of MEA Market Size and Forecast, by Stage
      • 16.6.12.8 Rest of MEA Market Size and Forecast, by Component
      • 16.6.12.9 Rest of MEA Market Size and Forecast, by Process
      • 16.6.12.10 Local Competition Analysis
      • 16.6.12.11 Local Market Analysis

17: Competitive Landscape

  • 17.1 Overview
  • 17.2 Market Share Analysis
  • 17.3 Key Player Positioning
  • 17.4 Competitive Leadership Mapping
    • 17.4.1 Star Players
    • 17.4.2 Innovators
    • 17.4.3 Emerging Players
  • 17.5 Vendor Benchmarking
  • 17.6 Developmental Strategy Benchmarking
    • 17.6.1 New Product Developments
    • 17.6.2 Product Launches
    • 17.6.3 Business Expansions
    • 17.6.4 Partnerships, Joint Ventures, and Collaborations
    • 17.6.5 Mergers and Acquisitions

18: Company Profiles

  • 18.1 Crown Bioscience
    • 18.1.1 Company Overview
    • 18.1.2 Company Snapshot
    • 18.1.3 Business Segments
    • 18.1.4 Business Performance
    • 18.1.5 Product Offerings
    • 18.1.6 Key Developmental Strategies
    • 18.1.7 SWOT Analysis
  • 18.2 The Jackson Laboratory
    • 18.2.1 Company Overview
    • 18.2.2 Company Snapshot
    • 18.2.3 Business Segments
    • 18.2.4 Business Performance
    • 18.2.5 Product Offerings
    • 18.2.6 Key Developmental Strategies
    • 18.2.7 SWOT Analysis
  • 18.3 Charles River Laboratories
    • 18.3.1 Company Overview
    • 18.3.2 Company Snapshot
    • 18.3.3 Business Segments
    • 18.3.4 Business Performance
    • 18.3.5 Product Offerings
    • 18.3.6 Key Developmental Strategies
    • 18.3.7 SWOT Analysis
  • 18.4 Horizon Discovery
    • 18.4.1 Company Overview
    • 18.4.2 Company Snapshot
    • 18.4.3 Business Segments
    • 18.4.4 Business Performance
    • 18.4.5 Product Offerings
    • 18.4.6 Key Developmental Strategies
    • 18.4.7 SWOT Analysis
  • 18.5 WuXi AppTec
    • 18.5.1 Company Overview
    • 18.5.2 Company Snapshot
    • 18.5.3 Business Segments
    • 18.5.4 Business Performance
    • 18.5.5 Product Offerings
    • 18.5.6 Key Developmental Strategies
    • 18.5.7 SWOT Analysis
  • 18.6 Champion Oncology
    • 18.6.1 Company Overview
    • 18.6.2 Company Snapshot
    • 18.6.3 Business Segments
    • 18.6.4 Business Performance
    • 18.6.5 Product Offerings
    • 18.6.6 Key Developmental Strategies
    • 18.6.7 SWOT Analysis
  • 18.7 Oncodesign
    • 18.7.1 Company Overview
    • 18.7.2 Company Snapshot
    • 18.7.3 Business Segments
    • 18.7.4 Business Performance
    • 18.7.5 Product Offerings
    • 18.7.6 Key Developmental Strategies
    • 18.7.7 SWOT Analysis
  • 18.8 Xentech
    • 18.8.1 Company Overview
    • 18.8.2 Company Snapshot
    • 18.8.3 Business Segments
    • 18.8.4 Business Performance
    • 18.8.5 Product Offerings
    • 18.8.6 Key Developmental Strategies
    • 18.8.7 SWOT Analysis
  • 18.9 EPO Berlin-Buch
    • 18.9.1 Company Overview
    • 18.9.2 Company Snapshot
    • 18.9.3 Business Segments
    • 18.9.4 Business Performance
    • 18.9.5 Product Offerings
    • 18.9.6 Key Developmental Strategies
    • 18.9.7 SWOT Analysis
  • 18.10 Pharmatest Services
    • 18.10.1 Company Overview
    • 18.10.2 Company Snapshot
    • 18.10.3 Business Segments
    • 18.10.4 Business Performance
    • 18.10.5 Product Offerings
    • 18.10.6 Key Developmental Strategies
    • 18.10.7 SWOT Analysis
  • 18.11 Shanghai LIDE Biotech
    • 18.11.1 Company Overview
    • 18.11.2 Company Snapshot
    • 18.11.3 Business Segments
    • 18.11.4 Business Performance
    • 18.11.5 Product Offerings
    • 18.11.6 Key Developmental Strategies
    • 18.11.7 SWOT Analysis
  • 18.12 Aragen Bioscience
    • 18.12.1 Company Overview
    • 18.12.2 Company Snapshot
    • 18.12.3 Business Segments
    • 18.12.4 Business Performance
    • 18.12.5 Product Offerings
    • 18.12.6 Key Developmental Strategies
    • 18.12.7 SWOT Analysis
  • 18.13 Biomodels
    • 18.13.1 Company Overview
    • 18.13.2 Company Snapshot
    • 18.13.3 Business Segments
    • 18.13.4 Business Performance
    • 18.13.5 Product Offerings
    • 18.13.6 Key Developmental Strategies
    • 18.13.7 SWOT Analysis
  • 18.14 Living Tumor Laboratory
    • 18.14.1 Company Overview
    • 18.14.2 Company Snapshot
    • 18.14.3 Business Segments
    • 18.14.4 Business Performance
    • 18.14.5 Product Offerings
    • 18.14.6 Key Developmental Strategies
    • 18.14.7 SWOT Analysis
  • 18.15 MI Bioresearch
    • 18.15.1 Company Overview
    • 18.15.2 Company Snapshot
    • 18.15.3 Business Segments
    • 18.15.4 Business Performance
    • 18.15.5 Product Offerings
    • 18.15.6 Key Developmental Strategies
    • 18.15.7 SWOT Analysis
  • 18.16 Altasciences
    • 18.16.1 Company Overview
    • 18.16.2 Company Snapshot
    • 18.16.3 Business Segments
    • 18.16.4 Business Performance
    • 18.16.5 Product Offerings
    • 18.16.6 Key Developmental Strategies
    • 18.16.7 SWOT Analysis
  • 18.17 Explora BioLabs
    • 18.17.1 Company Overview
    • 18.17.2 Company Snapshot
    • 18.17.3 Business Segments
    • 18.17.4 Business Performance
    • 18.17.5 Product Offerings
    • 18.17.6 Key Developmental Strategies
    • 18.17.7 SWOT Analysis
  • 18.18 Biocytogen
    • 18.18.1 Company Overview
    • 18.18.2 Company Snapshot
    • 18.18.3 Business Segments
    • 18.18.4 Business Performance
    • 18.18.5 Product Offerings
    • 18.18.6 Key Developmental Strategies
    • 18.18.7 SWOT Analysis
  • 18.19 Envigo
    • 18.19.1 Company Overview
    • 18.19.2 Company Snapshot
    • 18.19.3 Business Segments
    • 18.19.4 Business Performance
    • 18.19.5 Product Offerings
    • 18.19.6 Key Developmental Strategies
    • 18.19.7 SWOT Analysis
  • 18.20 GenenDesign
    • 18.20.1 Company Overview
    • 18.20.2 Company Snapshot
    • 18.20.3 Business Segments
    • 18.20.4 Business Performance
    • 18.20.5 Product Offerings
    • 18.20.6 Key Developmental Strategies
    • 18.20.7 SWOT Analysis